Postdoc
- Employer
- Pharmaceutical Sciences, Icahn School of Medicine at Mount Sinai
- Location
- New York City, New York (US)
- Salary
- Salary + subsidized housing + benefits
- Closing date
- Jun 18, 2022
View more
- Discipline
- Life Sciences, Biomedical Sciences, Biotechnology, Cell Biology, Analytical Chemistry, Biomedical Engineering
- Position Type
- Full Time
- Job Type
- Postdoc, Postdoc Fellowship, Research Scientist
- Organization Type
- Academia
Multiple postdoctoral positions are immediately available in the Center for Protein Engineering and Therapeutics, Department of Pharmacological Sciences, at Icahn School of Medicine at Mount Sinai in NYC.
The lab is interested in developing biotechnologies for the analysis of biomolecules and macromolecular assemblies, with a focus on mass spectrometry/proteomic techniques. Recently, inspired by the translational potential of nanobodies, our lab has developed robust integrative technologies to facilitate nanobody drug discovery and therapeutic applications. An emerging direction of the lab is to identify novel disease targets and develop effective protein therapeutics against various human diseases. The lab is vibrant, fun, and collaborative and supports creative ideas and career development.
References:
Xiang, Y., et al (2020). Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science.
Nambulli., et al (2021). Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Science Advances.
Xiang, Y., et al (2021). Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies. Cell Systems.
Sun, et al. (2021). Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes. Nature Communications.
Shen et al. (2021). A resource of high-quality nanobodies for drug delivery. iScience.
Sang, et al. (2021) Llamanade: an open-source computational pipeline for robust nanobody humanization. Structure.
Xiang et al (2022). Super-immunity by broadly protective nanobodies to sarbecoviruses. BioRxiv.
Jerome et al (2022). Reduced antigenicity of Omicron lowers host serologic response. BioRxiv.
Motivated individuals with a background in mass spectrometry, microbiology, and cancer immunology (ideally with in vivo disease model experience) or chemical biology are particularly welcome to apply. Candidates may submit their CV, including names and contact information for two-three references, a short description of their research experience, and goals to Dr. Yi Shi at (wally.yis@gmail.com). Competitive salaries will be provided for successful candidates.
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert